US RE50,391 E1
ROR1 antibody immunoconjugates
Brian Lannutti, Solana Beach, CA (US); Katti Jessen, San Diego, CA (US); Thanh-Trang Vo, San Diego, CA (US); and Jeffry Dean Watkins, Encinitas, CA (US)
Assigned to VelosBio Inc., Rahway, NJ (US)
Filed by VelosBio Inc., Rahway, NJ (US)
Filed on Jul. 1, 2021, as Appl. No. 17/365,293.
Application 17/365,293 is a continuation of application No. 16/016,238, filed on Jun. 22, 2018, abandoned.
Application 17/365,293 is a reissue of application No. 16/027,967, filed on Jul. 5, 2018, granted, now 10,335,496, issued on Jul. 2, 2019.
Claims priority of provisional application 62/524,386, filed on Jun. 23, 2017.
Claims priority of provisional application 62/524,388, filed on Jun. 23, 2017.
Claims priority of provisional application 62/524,382, filed on Jun. 23, 2017.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 38/05 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 47/6849 (2017.08) [A61K 38/05 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6811 (2017.08); A61K 47/6871 (2017.08); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the VH and VL of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is
ADC-A, having the structure

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein Ab in the structure is the antibody [ of the formula:
Ab-[(L)m-(D)]n
wherein Ab is an antibody that binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1), and wherein
Ab comprises:
(a) a heavy chain variable region (VH) comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 7, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 8; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 9, and
(b) a light chain variable region (VL) comprising an LCDRI comprising the amino acid sequence of SEQ ID NO: 10; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 11; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 12,
each occurrence of the group -[(L)m-(D)] has the structure:

OG Complex Work Unit Chemistry
wherein custom character represents the site of attachment to a sulfur atom on a cysteine residue on [the antibody] Ab; and
n is an integer from 1 to 8] .